Reduction of the clinical severity of sickle cell/β-thalassemia with hydroxyurea: The experience of a single center in Greece

Blood Cells, Molecules, and Diseases

Volumn 26, Issue 5, 2000, Pages 453-466

  Loukopoulos, D ^a   Voskaridou, E ^a   Kalotychou, V ^a   Schina, M ^a   Loutradi, A ^a   Theodoropoulos, I ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Hemoglobin F; Hydroxyurea; Sickle cell disease; Vasoocclusive crises

Indexed keywords

ALPHA GLOBIN; GAMMA GLOBIN; HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA;

ABDOMINAL DISCOMFORT; ACUTE PANCREATITIS; ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHOLESTASIS; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; GREECE; HEMOLYSIS; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; TREATMENT OUTCOME;

EID: 0034521888     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2000.0328     Document Type: Article

References (30)

1. Clinical trials with hydroxyurea and recombinant erythropoietin
2. Clinical and laboratory effects of long term administration of hydroxyurea to patients with sickle cell/beta-thalassemia
3. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
4. Hemoglobin variants and thalassemia in Greece
5. Determination of density distribution of red cell populations
6. β-Thalassemia mutations and the underlying β gene cluster haplotypes in the Greek population
7. Hematologic responses of sickle cell patients treated with hydroxyurea
8. The origin of the sickle cell mutation in Greece: Evidence from beta S globin gene cluster polymorphisms
9. Administration of hydroxyurea in patients with sickle cell disease induces an inappropriately high secretion of erythropoietin
10. The β-thalassemias
11. Levels of fetal hemoglobin necessary for treatment of sickle cell disease
12. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing cell differentiation kinetics
13. Mechanism of HbF stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C or hydroxyurea
14. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia
15. Stimulation of F-cell production in patients with sickle-cell anemia treated cytarabine or hydroxyurea
16. Hydroxyurea induction of hemoglobin F production in sickle cell disease: Relationship between cytotoxicity and F cell production
17. The relative importance of the X-linked FCP locus and beta-globin haplotypes in determining haemoglobin F levels: A study of SS patients homozygous for beta S haplotypes
18. Evolving therapies in globin gene disorders
19. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea
20. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea
21. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia
22. Management of sickle cell disease: Recent advances and controversies
23. Mortality in sickle cell disease: Life expectancy and risk factors for early death
24. From efficacy to safety: A Polycythemia Vera Study group report in patients with polycythemia vera
25. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea
26. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk
27. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial
28. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease
29. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial
30. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. American Society of Hematology 41st Annual Meeting